Cardiff Oncology Dirección
Dirección controles de criterios 3/4
El CEO de Cardiff Oncology es Mark Erlander , nombrado en May 2020, tiene una permanencia de 4.5 años. compensación anual total es $1.55M, compuesta por 38.4% salario y 61.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.048% de las acciones de la empresa, por valor de $59.98K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 10.2 años, respectivamente.
Información clave
Mark Erlander
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 38.4% |
| Permanencia del CEO | 4.5yrs |
| Participación del CEO | 0.05% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 10.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
Nov 07We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Oct 09
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Oct 04We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely
Jun 19Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Mar 09We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Mar 03Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Nov 16Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 01Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Feb 22Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Sep 14Cardiff Oncology: Down But Not Out
Aug 22Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Jun 20Cardiff Oncology: Upcoming Readouts And Several Green Lights
Jun 07Cardiff Oncology: Risky Investment
May 19Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance
Mar 01We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
Jan 28Cardiff: The Pfizer Interest Is Interesting
Dec 15Circling Back On Cardiff Oncology
Oct 12Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Aug 26Cardiff Oncology: Current Slump Doesn't Look Right
Jun 14Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation
Apr 29How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?
Feb 28What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
Jan 24Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$41m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$2m | US$594k | -US$41m |
| Sep 30 2023 | n/a | n/a | -US$41m |
| Jun 30 2023 | n/a | n/a | -US$40m |
| Mar 31 2023 | n/a | n/a | -US$39m |
| Dec 31 2022 | US$2m | US$571k | -US$39m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$4m | US$533k | -US$28m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$1m | US$445k | -US$23m |
| Sep 30 2020 | n/a | n/a | -US$20m |
| Jun 30 2020 | n/a | n/a | -US$20m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | US$853k | US$399k | -US$17m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$909k | US$387k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$18m |
| Mar 31 2018 | n/a | n/a | -US$20m |
| Dec 31 2017 | US$1m | US$374k | -US$25m |
Compensación vs. Mercado: La compensación total de Mark($USD1.55M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Mark ha sido consistente con los resultados de la empresa en el último año.
CEO
Mark Erlander (64 yo)
4.5yrs
Permanencia
US$1,547,772
Compensación
Dr. Mark Erlander, Ph D., is Chief Executive Officer of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since May 2020 and was its Chief Scientific Officer March 4, 2013 to April 2020. Dr. Erlan...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.5yrs | US$1.55m | 0.048% $ 60.0k | |
| Chief Financial Officer | 3.3yrs | US$917.72k | 0.12% $ 147.0k | |
| Chief Medical Officer | 1.8yrs | US$1.26m | 0% $ 0 | |
| Chief Scientific Officer | 2.8yrs | US$4.17m | 0% $ 0 | |
| VP of Finance & Administration | 9.3yrs | sin datos | sin datos | |
| Senior Vice President of Finance | 1.8yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | 2.8yrs | sin datos | sin datos |
2.8yrs
Permanencia media
61.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CRDF se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.4yrs | US$1.55m | 0.048% $ 60.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.6yrs | US$114.43k | 1.36% $ 1.7m | |
| Member of Scientific Advisory Board | 10.3yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 12yrs | US$35.85k | sin datos | |
| Independent Chairman of the Board | 10.8yrs | US$154.43k | 0.061% $ 76.1k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 14.6yrs | sin datos | sin datos | |
| Independent Director | 4.6yrs | US$116.43k | 0.22% $ 278.8k | |
| Member of Scientific Advisory Board | 10.2yrs | sin datos | sin datos | |
| Independent Director | 3.4yrs | US$110.43k | 0.020% $ 24.5k | |
| Member of Scientific Advisory Board | 14.6yrs | sin datos | sin datos |
10.2yrs
Permanencia media
72yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CRDF son experimentados ( 10.2 años antigüedad media).